Développement musculaire

At a Glance

Overview

The Basics

Muscle-building peptides do not describe one mechanism class. The local KB groups together compounds that increase endogenous GH release, compounds that act downstream as growth factors, a myostatin inhibitor, and several blend SKUs that mostly repackage the same CJC no-DAC plus ipamorelin pairing.

That is why this page works as a function map rather than as a protocol. The useful question is not which member belongs in a giant stack. The useful question is which biological lane is actually under discussion.

cjc-1295, sermorelin, and tesamorelin occupy the GHRH lane. ipamorelin, ghrp-2, ghrp-6, hexarelin, and mk-677 occupy the ghrelin-pathway secretagogue lane. igf-1-lr3 and peg-mgf occupy the downstream growth-factor lane. follistatin-344 occupies the myostatin lane. The four CJC no-DAC/ipamorelin blends plus hulk-blend occupy the blend lane.

The Science

The GH secretagogue lane works by increasing endogenous GH output. That lane splits into two mechanistic subgroups: GHRH receptor agonists and GHS-R1a agonists. The local guides repeatedly note that these two pathways can amplify each other, which is the main scientifically real synergy narrative in the collection.

The growth-factor lane changes the level of intervention. igf-1-lr3 directly stimulates IGF-1 receptor signaling and bypasses much of the upstream endocrine regulation that secretagogues still depend on. peg-mgf sits closer to repair and regeneration signaling than to straightforward size gain.

The myostatin lane changes the frame again. follistatin-344 removes inhibitory signaling around muscle growth, but the local KB also stresses that the strongest results come from gene-therapy models rather than short-lived injectable peptide cycles.

How It Works / Synergy Analysis

The Basics

The collection makes the most sense when each lane is kept separate.

The GH secretagogue lane contains the only broadly defensible synergy story. One GHRH analog paired with one ghrelin-pathway secretagogue can make mechanistic sense because the pathways are different. The collection does not support flattening that into a rule that more secretagogues are always better.

The growth-factor and myostatin lanes are not extensions of the same logic. igf-1-lr3 is already downstream and more direct. peg-mgf is more repair-oriented. follistatin-344 removes a growth brake rather than amplifying GH pulses.

The Science

cjc-1295, sermorelin, and tesamorelin work through the GHRH receptor and cAMP/PKA signaling. ipamorelin, ghrp-2, ghrp-6, hexarelin, and mk-677 work through GHS-R1a and calcium-mobilization signaling. The local guides for ghrp-2, ghrp-6, sermorelin, hexarelin, ipamorelin, and mk-677 all point back to this complementary biology.

That complement does not apply cleanly inside the ghrelin-pathway subgroup itself. ipamorelin, ghrp-2, ghrp-6, hexarelin, and mk-677 already compete inside the same receptor family. Redundancy, appetite escalation, cortisol and prolactin drift, edema, tachyphylaxis, and glucose burden become more likely than clean additive GH benefit.

The downstream lane carries different tradeoffs. igf-1-lr3 activates PI3K-AKT-mTOR and MAPK signaling directly, which is why it attracts interest for hyperplasia and recovery but also why the safety conversation becomes sharper. peg-mgf is better framed around recovery, satellite-cell activation, and tissue repair than around obvious standalone hypertrophy. follistatin-344 is strongest on paper in myostatin biology, yet the local KB repeatedly warns that the injectable peptide format does not match the dramatic gene-therapy literature.

Key Benefits & Goals

The Basics

This collection covers four distinct muscle-building conversations:

• endogenous GH release and recovery support;
• appetite-supported or sleep-supported body-composition work inside the ghrelin lane;
• direct anabolic growth signaling through IGF biology;
• growth-brake removal through myostatin inhibition.

That separation matters because all four are often marketed under the same hypertrophy umbrella even though the biology, evidence, and risk are different.

The Science

The strongest evidence-backed benefits in the collection are narrower than the marketing language around "muscle building" often suggests.

• tesamorelin has the strongest human data for body-composition change, especially visceral-fat reduction with lean-mass preservation.
• sermorelin, cjc-1295, and ipamorelin are most credible for GH-axis support, recovery, sleep quality, and gradual body-composition effects rather than dramatic mass gain.
• ghrp-2, ghrp-6, hexarelin, and mk-677 can produce a more forceful secretagogue signal, but the tradeoffs become more obvious.
• igf-1-lr3 is the direct-growth-signal member, with the clearest mechanistic argument for aggressive anabolic signaling.
• peg-mgf is stronger on repair than on visible size gain.
• follistatin-344 is strongest in theory and weakest in translational certainty for normal peptide-cycle use.

Evidence Summary

The Basics

The evidence hierarchy is mixed enough that the collection should stay comparative and restrained.

tesamorelin has the best human clinical footing in the set. sermorelin, cjc-1295, ipamorelin, ghrp-2, ghrp-6, hexarelin, and mk-677 all have real GH-axis literature, but their direct hypertrophy evidence is thinner than their marketing suggests. igf-1-lr3, peg-mgf, and follistatin-344 sit in more experimental territory despite sounding more overtly anabolic.

The Science

Evidence calibration across the collection:

• Strongest human-data member: tesamorelin
• Moderate human GH-axis footing: sermorelin, cjc-1295, ipamorelin, ghrp-2, ghrp-6, hexarelin, mk-677
• Low-to-moderate experimental footing: igf-1-lr3, peg-mgf
• Large mechanism-to-translation gap: follistatin-344
• No standalone local evidence base: cjc-no-dac-ipamorelin-5mg, cjc-no-dac-ipamorelin-10mg, ipamorelin-cjc-no-dac-5-5mg, ipamorelin-cjc-no-dac-10-10mg, hulk-blend

The collection therefore supports lane comparison better than it supports a single ranked list of "best mass builders."

Component Highlights

Quick links: CJC-1295, Follistatin-344, GHRP-2, GHRP-6, Hexarelin, IGF-1 LR3, Ipamorelin, MK-677, PEG-MGF, Sermorelin, Tesamorelin. Registry-only blend members are summarized below without dedicated guide links in this pass.

CJC-1295

CJC-1295 is the flexible GHRH lane comparator. The local KB supports it more for GH-pulse support, recovery, and pairing logic with ghrelin-pathway agents than for isolated mass-building outcomes.

Follistatin-344

Follistatin-344 is the myostatin lane. Its appeal is obvious, but the local KB makes the evidence gap obvious too: gene-therapy and animal data are much stronger than short injectable-peptide evidence.

GHRP-2

GHRP-2 is the middle ground ghrelin-pathway secretagogue. It is stronger and messier than ipamorelin, with more appetite and more endocrine noise, but less appetite dominance than GHRP-6.

GHRP-6

GHRP-6 is the appetite-forward secretagogue. In muscle-building conversations it is often included less because it is uniquely anabolic and more because it makes eating easier.

Hexarelin

Hexarelin is the high-potency secretagogue. The local KB repeatedly places tachyphylaxis and broader side effects next to that potency, which limits its role as a stable long-cycle option.

IGF-1 LR3

IGF-1 LR3 is the direct growth-factor entry. It belongs in a separate lane because it bypasses the upstream GH-pulse question and moves directly into proliferative signaling.

Ipamorelin

Ipamorelin is the cleanest ghrelin-pathway comparator. The local KB frames it around selectivity, sleep, recovery, and compatibility with GHRH analogs rather than dramatic size gain on its own.

MK-677

MK-677 is the oral ghrelin-pathway comparator. It is not a peptide, but it belongs in the collection because it occupies the same functional GH-secretagogue lane and is constantly compared against injectable options.

PEG-MGF

PEG-MGF is better described as a repair-oriented growth factor than as a primary hypertrophy driver. The local KB is consistent on that point.

Sermorelin

Sermorelin is the evidence-mature GHRH analog. The local KB gives it the strongest clinical-history advantage in the GHRH subgroup and treats it as a logical pairing partner for ghrelin-pathway agents.

Tesamorelin

Tesamorelin is the strongest human-data member in the collection. That makes it important, but its clinical strength comes from body-composition studies rather than direct bodybuilding-style hypertrophy trials.

CJC No DAC / Ipamorelin 5mg

This blend is a packaging variant of the CJC no-DAC plus ipamorelin lane. The local KB supports the component pairing, not a separate blend-specific evidence base.

CJC No DAC / Ipamorelin 10mg

This is the same blend concept at a higher package strength. The mechanism does not change with the label.

Ipamorelin + CJC No DAC 5/5mg

This is the same pairing written in reverse order. The local normalization utility explicitly treats order-swapped dosage blends as duplicates.

Ipamorelin + CJC No DAC 10/10mg

This is the higher-strength duplicate of the same pairing. It is a formulation variant, not a new lane.

Hulk Blend

Hulk Blend is a registry-only member in the current local KB. The collection can acknowledge its presence, but the absence of local composition documentation means it should remain under-described rather than guessed at.

Comparative Analysis

The Basics

The cleanest comparison framework is lane-based rather than hype-based.

• sermorelin, cjc-1295, and tesamorelin compare inside the GHRH subgroup.
• ipamorelin, ghrp-2, ghrp-6, hexarelin, and mk-677 compare inside the ghrelin-pathway subgroup.
• igf-1-lr3 and peg-mgf compare inside the downstream growth-factor subgroup.
• follistatin-344 sits alone in the myostatin subgroup.
• the blend SKUs compare only as packaging variants.

The Science

The practical comparison points are:

• For strongest human evidence: tesamorelin
• For longest GHRH clinical history: sermorelin
• For flexible GHRH pairing logic: cjc-1295
• For cleanest ghrelin-pathway selectivity: ipamorelin
• For stronger appetite and broader endocrine push: ghrp-2 and ghrp-6
• For strongest acute ghrelin-pathway potency with desensitization risk: hexarelin
• For oral continuous secretagogue coverage: mk-677
• For direct receptor-level anabolic signaling: igf-1-lr3
• For repair-oriented growth-factor framing: peg-mgf
• For myostatin inhibition theory with the widest translation gap: follistatin-344

Getting Started

The Basics

The collection is organized around function selection rather than around stack construction.

The first distinction is whether the conversation is still about endogenous GH release or has already moved into direct growth-factor or myostatin territory. The second distinction is whether a blend product adds convenience only or actually changes the biology. In this set, the blend members mostly add naming and concentration variation, not a new mechanism.

The Science

The local KB supports four interpretive rules:

1. GHRH analogs and ghrelin-pathway secretagogues can complement each other.
2. Multiple ghrelin-pathway agonists do not automatically become better together.
3. Direct growth factors and myostatin inhibitors change the safety and evidence conversation rather than simply extending the GH secretagogue lane.
4. Blend SKUs inherit the logic of their components unless local documentation proves otherwise.

General Dosing Considerations

The Basics

This collection is not suitable as a single dosing template.

The members span short-half-life injectables, longer-acting analogs, an oral secretagogue, direct growth factors, a myostatin inhibitor with a major translation gap, and blend products with overlapping component logic. That is not one protocol language.

The Science

At the collection level, dosing remains a member-specific issue because half-life, route, cadence, and monitoring differ sharply:

• GHRH analogs are usually scheduled around pulse timing and IGF-1 monitoring.
• Ghrelin-pathway secretagogues are constrained by appetite, glucose, cortisol, prolactin, or tachyphylaxis considerations depending on the compound.
• igf-1-lr3 and peg-mgf operate on different exposure and risk assumptions.
• follistatin-344 is especially poorly served by casual dose extrapolation because the strongest evidence does not come from standard injectable peptide cycles.

What to Expect

The Basics

The first noticeable effects differ by lane.

GH secretagogues usually surface through sleep, appetite, recovery, fluid shifts, or gradual body-composition changes. mk-677 often declares itself through appetite, sleep, edema, and glucose effects. igf-1-lr3 and peg-mgf are less predictable and more confounded by training, food intake, and other stack variables. follistatin-344 has the widest gap between mechanistic expectation and reliably attributable short-cycle outcomes.

The Science

Rough response windows across the collection:

• Days 1-7: appetite, sleep, flushing, or water-retention signals in the ghrelin-pathway subgroup; very little visible muscle gain
• Weeks 2-4: recovery, training tolerance, and early body-composition effects become more visible for responsive GH-secretagogue users
• Weeks 4-8: clearer divergence between cleaner secretagogue profiles, appetite-heavy profiles, and more experimental downstream-growth-factor effects
• Weeks 8-12+: where the difference between steady GH-axis support and speculative anabolic escalation becomes easier to see

The central expectation-setting point is simple: most secretagogues in this collection are better documented for endocrine or body-composition signaling than for dramatic independent hypertrophy.

Safety & Interactions

The Basics

The easiest way to misuse this collection is to treat every member as part of one escalating anabolic ladder. The local KB does not support that. The members sit in different lanes because they create different kinds of risk.

The cleanest GH secretagogue logic is one GHRH analog plus one ghrelin-pathway secretagogue. Beyond that point, overlap tends to rise faster than clarity.

The Science

The major safety themes by lane are:

• GHRH analogs: IGF-1 elevation, edema, and member-specific niche effects; tesamorelin carries the strongest monitoring expectations because the human data is strongest
• Ghrelin-pathway secretagogues: appetite escalation (ghrp-6, mk-677), cortisol and prolactin drift (ghrp-2, ghrp-6, hexarelin), tachyphylaxis (ghrp-2, especially hexarelin), glucose and edema burden (mk-677)
• Direct growth factors: hypoglycemia, edema, poor monitoring clarity, and proliferative-risk framing with igf-1-lr3
• Repair-oriented growth factors: thin evidence and attribution problems with peg-mgf
• Myostatin inhibition: dramatic mechanism claims with weak peptide-format translational support in follistatin-344
• Blend products: duplicated biology can look like extra sophistication when it is mostly extra naming

Stacking patterns that should not be normalized include multiple GHS-R agonists in parallel, automatic addition of igf-1-lr3 on top of already aggressive GH-secretagogue protocols, and treating follistatin-344 peptide cycles as interchangeable with gene-therapy results.

Related Peptide Guides

• CJC-1295 — GHRH analog and core reference point for the no-DAC blend lane
• Follistatin-344 — myostatin and activin blockade lane
• GHRP-2 — ghrelin-pathway secretagogue with moderate appetite and endocrine spillover
• GHRP-6 — appetite-dominant ghrelin-pathway secretagogue
• Hexarelin — highest-potency ghrelin-pathway secretagogue with rapid tachyphylaxis
• IGF-1 LR3 — direct downstream growth-factor analog
• Ipamorelin — cleanest ghrelin-pathway comparator
• MK-677 — oral non-peptide comparator in the same secretagogue lane
• PEG-MGF — repair-oriented growth-factor analog
• Sermorelin — evidence-mature GHRH analog
• Tesamorelin — strongest human-data member in the collection

Sources & References

• docs/peptide-guides/kb/cjc-1295/research-summary.md
• docs/peptide-guides/kb/cjc-1295/guide-draft.md
• docs/peptide-guides/kb/follistatin-344/research-summary.md
• docs/peptide-guides/kb/follistatin-344/guide-draft.md
• docs/peptide-guides/kb/ghrp-2/research-summary.md
• docs/peptide-guides/kb/ghrp-2/guide-draft.md
• docs/peptide-guides/kb/ghrp-6/research-summary.md
• docs/peptide-guides/kb/ghrp-6/guide-draft.md
• docs/peptide-guides/kb/hexarelin/research-summary.md
• docs/peptide-guides/kb/hexarelin/guide-draft.md
• docs/peptide-guides/kb/igf-1-lr3/research-summary.md
• docs/peptide-guides/kb/igf-1-lr3/guide-draft.md
• docs/peptide-guides/kb/ipamorelin/research-summary.md
• docs/peptide-guides/kb/ipamorelin/guide-draft.md
• docs/peptide-guides/kb/mk-677/research-summary.md
• docs/peptide-guides/kb/mk-677/guide-draft.md
• docs/peptide-guides/kb/peg-mgf/research-summary.md
• docs/peptide-guides/kb/peg-mgf/guide-draft.md
• docs/peptide-guides/kb/sermorelin/research-summary.md
• docs/peptide-guides/kb/sermorelin/guide-draft.md
• docs/peptide-guides/kb/tesamorelin/research-summary.md
• docs/peptide-guides/kb/tesamorelin/guide-draft.md
• docs/peptide-guides/kb/_peptide-registry.md
• src/lib/peptide/normalize-peptide.ts